Your browser doesn't support javascript.
COVID-19 Pandemic Impact on Cord Blood Collection for Stem Cell Use and Actual Perspectives.
Daia, Mihail Tiberiu; Median, Dragos; Buinoiu, Natalia Florina; Ciocarlan, Maria; Iancu, George; Panaitescu, Anca Maria; Peltecu, Gheorghe; Streinu-Cercel, Adrian.
  • Daia MT; Filantropia Clinical Hospital, Bucharest, Romania.
  • Median D; Filantropia Clinical Hospital, Bucharest, Romania.
  • Buinoiu NF; Gral Medical, Bucharest.
  • Ciocarlan M; Filantropia Clinical Hospital, Bucharest, Romania.
  • Iancu G; Filantropia Clinical Hospital, Bucharest, Romania.
  • Panaitescu AM; Filantropia Clinical Hospital, Bucharest, Romania.
  • Peltecu G; Filantropia Clinical Hospital, Bucharest, Romania.
  • Streinu-Cercel A; "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
Maedica (Bucur) ; 16(2): 184-188, 2021 Jun.
Article in English | MEDLINE | ID: covidwho-1464181
ABSTRACT

Objective:

The aim of the current study is to assess the prevalence of hepatitis B and the risk of hepatitis reactivation in carriers of hepatitis B virus (HBV) cancer patients who underwent chemotherapy for gynecologic and/or breast cancers in a single institution, during a period of five years, and to identify a relationship to some particular chemotherapy regimen, more prone to lead to reactivation. Material and

methods:

We conducted a retrospective chart review on all consecutive oncological patients treated for a gynecologic and/or breast cancers who presented for the first time to the Gynecologic Oncology Department of Filantropia Hospital, Bucharest, Romania, between January 2016 and December 2020.

Results:

A total of 1 895 patients diagnosed with ovarian, cervical, endometrial or breast cancers were admitted to hospital for systemic therapy during the mentioned period. Among these, only four patients (two patients with breast cancers, one cervical cancer and one endometrial carcinoma) were chronic carriers of HBV surface antigen (HBsAg positive). Patients received a variety of chemotherapeutic regimens including corticosteroids, gemcitabine, cisplatin, carboplatin, taxanes and anthracyclines. We report one reactivation that occurred in one occult carrier of hepatitis B virus diagnosed with breast cancer (HBsAg negative, hepatitis B core antibody positive - HBcAb), initially excluded from this study, as being screened negative for HBV, treated with taxanes-based chemotherapy and corticosteroids.

Conclusion:

HBV reactivation had a low incidence in our population of patients diagnosed with gynecologic or breast cancer who received systemic chemotherapy. The HBV reactivation risk was positively correlated with breast cancer and to taxanes-based regimens and glucocorticoids. Further studies to identify additional risk factors of HBV infection reactivation in gynecologic oncology patients and possible risk reducing measures are warranted.

Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Observational study / Prognostic study Language: English Journal: Maedica (Bucur) Year: 2021 Document Type: Article Affiliation country: Maedica.2021.16.2.189

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Observational study / Prognostic study Language: English Journal: Maedica (Bucur) Year: 2021 Document Type: Article Affiliation country: Maedica.2021.16.2.189